English

ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna

Report this content

Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that filmed company presentations in which CEO Bent Frandsen shared insights into the company’s development strategy and value creation potential are now available on the company’s website.

The first presentation was delivered at the Biostock Life Science Summit on 21 November 2024. The second took place at the Aktiespararna event Stora Aktiedagarna in Stockholm on 27 November 2024. Both presentations highlighted ExpreS2ion’s novel HER2-targeted therapeutic cancer vaccine program, ES2B-C001, and the company's progress toward key milestones.

Key topics covered include:

  • The unmet medical need for HER2-positive cancer treatments and the transformative potential of ES2B-C001
  • Strong preclinical data, demonstrating significant tumour growth inhibition and survival outcomes
  • The company’s integrated development plan (iDP), positioning ExpreS2ion for value creation through strategic milestones, including the anticipated decision on the Phase I clinical trial application.

The presentations can be found on the Company’s investor website via the following link: https://investor.expres2ionbio.com/presentations/

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Subscribe

Documents & Links